Article thumbnail

Imatinib as the first and only treatment in Europe for adult patients at significant risk of relapse following gastrointestinal stromal tumor removal

By F Duffaud, S Salas, T Huyn and JL Deville


Mutations of the KIT gene are the molecular hallmark of most gastrointestinal stromal tumors (GISTs). GIST has become a model for targeted treatment of solid tumors, imatinib becoming the standard first-line treatment of these tumors in the advanced/metastatic phase. Because of the efficacy of imatinib treatment in the advanced setting, its role following resection of a primary non-metastatic GIST was investigated. The recently published phase III, double-blind, placebo-controlled, multicenter ACOSOG Z9001 study showed that adjuvant therapy is safe, and significantly improves recurrence-free survival compared to placebo when given after resection. To what extent imatinib will improve overall survival has yet to be answered. What is clear is that high-risk GIST patients definitely need adjuvant therapy, and that 1 year of imatinib is not enough for the patients who do need it. The questions of optimal duration of imatinib treatment in the adjuvant setting, adequate selection of risk patients and effect of imatinib on overall survival are currently being studied

Topics: Review
Publisher: Dove Medical Press
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. [Epub ahead of print].
  2. A modification of NIH consensus criteria to better distinguish the highly lethal subset of primary localized gastrointestinal stromal tumors: a subdivision of the original high-risk group on the basis of outcome.
  3. A Review of its use in the management of gastrointestinal stromal tumors.
  4. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
  5. (2002). Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST).
  6. Adjuvant imatinib mesylate increases recurrence-free survival (RFS) in patients with completely resected localized primarygastrointestinale stromal tumor (GIST):
  7. (2007). Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours
  8. (2005). Clinical pharmacokinetics of imatinib. Clin Pharmacokinet.
  9. (2006). Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann Surg.
  10. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta analysis base don 1,640 patients (pts).
  11. (2007). Continuous versus interruption of imatinib (IM) in responding patients with advanced GIST after three years of treatment: A prospective randomized phase III trial of the French Sarcoma Group. J Clin Oncol. (Meeting Abstracts)
  12. Deletions affecting codons 557–558 of the c-kit gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors. A study by the Spanish group for sarcoma research (GEIS).
  13. development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastro-intestinal stromal tumour: a retrospective analysis. Lancet Oncol.
  14. (2002). Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol.
  15. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
  16. (2002). Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol.
  17. (1998). Familial gastrointestinal stromal tumours with germline mutation of the KIT gene. Nat Genet.
  18. for the ESMO Guidelines working Group. Gastrointestinal stromal tumors: ESMO clinical recommendations for diagnosis, treatment, and follow up. Ann Oncol.
  19. Gastrointestinal stromal tumor: 5 years later.
  20. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up.
  21. (2000). Gastrointestinal stromal tumors: current diagnosis, biologic behaviour, and management. Ann Surg Oncol.
  22. (2006). Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol.
  23. (2006). Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med.
  24. (2002). Gastrointestinal stromal tumour (GIST): biology and treatment. Ann Oncol.
  25. (2004). GIST consensus meeting panellist. Consensus meeting for the management of gastrointestinal stromal tumors.
  26. (2005). Gstrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinibmesylate era- a population based study in western Sweden.
  27. Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study.
  28. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
  29. Long-term results from a randomized phase II trial of standard versus versus higher-dose imatinib mesylate for patients with unresectable gastrointestinal stromal tumors expressing KIT.
  30. (2008). Molecular pathobiology of gastrointestinal stromal sarcomas. Annu Rev Pathol.
  31. (2004). NCCN Task Force report: optimal management of patients with gastrointestinal stromal tumor (GIST)–expansion and update of NCCN Clinical Practice Guidelines. J Natl Compr Canc Netw.
  32. NCCN Task Force. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)–update of the NCCN clinical practice guidelines.
  33. on behalf of the ESMO Guidelines Working Group. Gastrointestinal stromal tumors.: ESMO clinical recommendations for diagnosis, treatment, and follow-up. Ann Oncol. 2008;19(Suppl II):35–38.
  34. Outcome of patients with advanced gastro-intestinal stromal tumours crossing-over to a daily imatinib dose of 800 mg after progression of 400 mg.
  35. PDGFRA activating mutations in gastrointestinal stromal tumors.
  36. PDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumor.
  37. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vivo sensitivity.
  38. progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
  39. Prospective multicentric randomized phase III of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond one year: the French Sarcoma Group.
  40. (2008). Risk stratification of patients diagnosed with gastrointestinal stromal tumor. Hum Pathol.
  41. Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in the clinical outcome and expression of multidrug resistance proteins.
  42. Trends in incidence and surzvival ofmesenchymal neoplasm of the digestive tract within a defined population of northern Norway.
  43. (2008). Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor
  44. Tumor size is a major determinant of recurrence in patients with resectable gastrointestinal stromal tumor.
  45. (2000). Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg.
  46. (2005). Update on thebiology and therapy of gastrointestinal stromal tumors. Cancer Control.